首页
良性前列腺增生与前列腺癌之间组织炎症的病理学特征和差异
Differences in Pathological Features of Histological Inflammation Between Benign Prostatic Hyperplasia and Prostate Cancer
-
摘要: 目的 研究良性前列腺增生(BPH)及前列腺癌(PCa)患者的前列腺组织中组织炎症的病理学特征和差异。 方法 观察患者前列腺HE染色组织病理切片,判断有无组织炎症。将BPH和PCa中存在组织炎症的病理切片进行详细分析:①BPH和PCa患者前列腺组织中组织炎症的发生率;②根据炎症组织学分类的3个方面:解剖学位置、炎症范围和炎症程度,比较有组织炎症的BPH (BPH组)与有组织炎症的PCa患者(PCa组)之间的病理学特点和差异;③比较PCa组内病理学特征是否随前列腺特异抗原(PSA)的升高和Gleason评分的变化而变化。 结果 ①前列腺穿刺标本组织炎症在BPH和PCa中的发生率分别为99.3%(142/143)和98.1%(104/106)。②病理检查发现BPH组(n=142)以腺周炎症为主(80例,占56.3%),PCa组(n=104)以间质炎症为主(59例,占56.7%),两组中组织炎症在解剖学位置上差异有统计学意义(P<0.05)。③BPH组以多灶性炎症为主(86例,占60.6%)。PCa组以局灶性炎症为主(53例,占51.0%),两组中组织炎症的炎症范围差异有统计学意义(P<0.05)。④BPH组以轻度炎症为主,其中轻度炎症101例(71.1%),中度炎症25例(17.6%),重度炎症16例(11.3%)。PCa组同样以轻度炎症为主,其中轻度炎症70例(67.3%),中度炎症31例(29.8%),重度炎症3例(2.9%);两组间中度、重度炎症差异有统计学意义(P<0.05),而轻度炎症差异无统计学意义(P=0.52)。⑤PCa组随着PSA水平的升高,间质炎症增多而腺体和腺周炎症逐渐减少(P<0.05);随着Gleason评分的升高,多灶性和弥漫性炎症明显增多而局灶性炎症逐渐减少(P<0.05)。 结论 组织炎症在BPH和PCa中的发生率高。BPH组织炎症以轻度、多灶性、腺周炎症为主,PCa组织炎症以轻度、局灶性、间质炎症为主。Abstract: Objective To study the pathologic features and differences of tissue inflammation in benign prostatic hyperplasia (BPH) and prostate cancer (PCa). Methods The HE stained slice obtained by prostate biopsy from 143 BPH and 106 PCa were reviewed to determine whether the tissue inflammation existed. According to the histological classification of prostatic tissue inflammation, the features of tissue inflammation and the differences of these features between the two groups were studied in detail. Results There were 142 cases found tissue inflammation in 143 BPH patients and 104 cases in 106 PCa patients, so the incidences of tissue inflammation in BPH and PCa were 99.3% and 98.1% respectively. The anatomical location of inflammation was significant difference between BPH and PCa group (P<0.05). The peri-glandular inflammation (56.3%) was primary in BPH, and interstitial inflammation (56.7%) was the main pattern in PCa. The inflammation range was also significant difference between the two groups (P<0.05). The inflammation was presented multifocally (60.6%) in BPH, and focal lesions (51.0%) was commonly found in PCa. Mild inflammation was most frequently observed in both groups (P>0.05). However, there were statistically significant differences between the two groups in the degree of moderate and severe inflammation (P<0.05). Conclusion The incidences of tissue inflammation were high in both BPH and PCa, but the pathological features of tissue inflammation were different between BPH and PCa.
-
Keywords:
- Prostatic hyperplasia /
- Prostate cancer /
- Tissue inflammation
-
-
[1] Parsons JK. Benign prostatic hyperplasia and male lower urinary tract symptoms:epidemiology and risk factors. Curr Bladder Dysfunct Rep,2010;5(4):212-218.
[2] Chughtai B, Lee R, Te A, et al. Inflammation and benign prostatic hyperplasia:clinical implications. Curr Urol Rep,2011;12(4):274-277.
[3] McLaren ID, Jerde TJ, Bushman W. Role of interleukins, IGF and stem cells in BPH. Differentiation,2011;82(4-5):237-243.
[4] Song L, Zhu Y, Han P, et al. A retrospective study:correlation of histologic inflammation in biopsy specimens of Chinese men undergoing surgery for benign prostatic hyperplasia with serum prostate-specific antigen. Urology,2011;77(3):688-692.
[5] Yi FX, Wei Q, Li H, et al. Risk factors for prostatic inflammation extent and infection in benign prostatic hyper-plasia. Asian J Androl,2006;8(5):621-627.
[6] Liu L, Li Q, Han P, et al. Evaluation of interleukin-8 in expressed prostatic secretion as a reliablebiomarker of inflammation in benign prostatic hyperplasia. Urology,2009;74(2):340-344.
[7] De Nunzio C, Kramer G, Marberger M, et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer:the role of inflammation. Eur Urol,2011;60(1):106-117.
[8] Nickel JC, True LD, Krieger JN, et al. Consensus development of a histopathological classification system for chronic prostatic inflammation. BJU International,2001;87(9):797-805.
[9] 叶定伟.PCa的流行病学和中国的发病趋势.中华外科杂志,2006;44(6):362-364. [10] Parsons JK. Benign prostatic hyperplasia and male lower urinary tract symptoms:epidemiology and risk factors. Curr Bladder Dysfunct Rep,2010;5(4):212-218.
[11] Cheng I, Witte JS, Jacobsen SJ, et al. Prostatitis, sexually transmitted diseases, and prostate cancer:the California Men's Health Study. PLoS ONE,2010;5(1):e8736.
[12] Daniels NA, Ewing SK, Zmuda JM, et al. Correlates and prevalence of prostatitis in a large community-based cohort of older men. Urology,2005;66(5):964-970.
[13] Gregory TM, Rosana E, Ranleigh LF, et al. The influence of chronic inflammation in prostatic carcinogenesis:a 5-year follow-up study. J Urol,2006;176(3):1012-1016.
[14] Robert G, Descazeauda A, Allory Y, et al. Should we investigate prostatic inflammation for the management of benign prostatic hyperplasia? Eur Urol Suppl,2009;8(13):879-886.
[15] Cosimo DN, Gero K, Michael M, et al. The controversial relationship between benign prostatichyperplasia and prostate cancer:the role of inflammation. Eur Urol,2011;60(1):106-117.
[16] Alessandro S, Franco DS, Stefano S, et al. Inflammation and chronic prostatic diseases:evidence for a link? Eur Urol,2007;52(4):964-972.
计量
- 文章访问数: 3428
- HTML全文浏览量: 171
- PDF下载量: 65
下载:
